NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia flag Australia · Delayed Price · Currency is AUD
0.1400
+0.0050 (3.70%)
Jan 30, 2026, 4:10 PM AEST

ASX:NSB Cash Flow Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 20212016 - 2020
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2016 - 2020
Net Income
-1.850.32-1.07-10.44-3.18
Upgrade
Depreciation & Amortization
0.090.090.060.060.06
Upgrade
Stock-Based Compensation
0.80.130.241.350.63
Upgrade
Change in Accounts Receivable
-0.04-0.010.08-0.07-0.03
Upgrade
Change in Accounts Payable
0.05-0.5-1.581.990.11
Upgrade
Change in Other Net Operating Assets
00.01-0.030.16-0.19
Upgrade
Operating Cash Flow
-0.940.04-2.3-6.94-2.6
Upgrade
Capital Expenditures
--0--0-0.03
Upgrade
Cash Acquisitions
-0.04----
Upgrade
Investing Cash Flow
-0.04-0--0-0.03
Upgrade
Issuance of Common Stock
3.5---13.32
Upgrade
Other Financing Activities
-0.21---0.18
Upgrade
Financing Cash Flow
3.29---13.51
Upgrade
Net Cash Flow
2.310.04-2.3-6.9510.88
Upgrade
Free Cash Flow
-0.940.04-2.3-6.95-2.63
Upgrade
Free Cash Flow Margin
-1.92%-46.52%--274.46%
Upgrade
Free Cash Flow Per Share
-0.01--0.02-0.05-0.02
Upgrade
Levered Free Cash Flow
-0.34-0.19-1.97-3.08-1.49
Upgrade
Unlevered Free Cash Flow
-0.34-0.18-1.97-3.08-1.49
Upgrade
Change in Working Capital
0.01-0.5-1.542.08-0.11
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.